Up­dat­ed: Study shows As­traZeneca's Covid-19 mAb Evusheld may not work against dom­i­nant Omi­cron strain

As­traZeneca’s pro­phy­lac­tic treat­ment for Covid-19, known as Evusheld, has sur­vived where oth­er mAbs failed, show­ing ef­fi­ca­cy for the im­muno­com­pro­mised and oth­ers who can­not be vac­ci­nat­ed across mul­ti­ple vari­ants, in­clud­ing Delta and sev­er­al Omi­cron sub­vari­ants.

But new cor­re­spon­dence pub­lished in the New Eng­land Jour­nal of Med­i­cine yes­ter­day says that the dom­i­nant Omi­cron sub­vari­ants right now are much less sus­cep­ti­ble to Evusheld, which is a com­bi­na­tion of tix­agevimab and cil­gav­imab. That da­ta may end up re­sult­ing in a pause in the use of Evusheld, al­though an As­traZeneca spokesper­son in­sists that it won’t, and HHS has not in­di­cat­ed that there’ll be a pause any­time soon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER